In June 2013, the US Food and Drug Administration (FDA) indicated that it was interested in making it easier to submit so-called "806 reports"-filings made to report the removal or correction of a medical device from the market for reasons related to human safety. Now the agency is moving forward with that proposal, submitting it this week for final government review.
Under 21 CFR 806.10, companies are required to make written "reports of corrections and removals" to the US Food and Drug Administration if one (or both) of two conditions are met:
Information about the recall or removal must be sent to FDA within 10 days of initiating the action, and the report must include 15 data points, including:
Even if such actions are not required to be reported to FDA, under 21 CFR 806.20(a), manufacturers are still required to keep a record of the correction or removal, though the report does not need to be submitted.
All 806 reports have traditionally been sent to FDA in paper format by mail-a relatively archaic process considering the vast majority of FDA's forms, including its adverse event reporting forms which are similar in nature to the 806 forms, may be submitted electronically.
However, that anachronism will soon change if FDA gets its way. In June 2013, FDA proposed the creation of an "electronic process for submitting 806 reports" on a voluntary basis.
While paper-based reporting would still be permitted, FDA said it expected that the electronic filing of Form 806s would enhance the consistency of the data it receives and expedite the submission process.
That process, it added, would result in process efficiencies, though it is not yet clear how much time-if any-would be saved by FDA or industry. "We believe that submitters will find the electronic submission process to be user friendly and that it will enhance the consistency of submission data," FDA wrote. "We estimate that an electronic report will take the same amount of time for the submitter as a paper report takes."
As conceived of by FDA, the process of electronic reporting would require users to establish a "WebTrader" account and a digital verification certificate, which would then be valid for up to three years. This certificate would need to be purchased, but otherwise the electronic submission process does not establish any other costs or burdens on the manufacturer.
Establishing the account may take as long as two weeks, per FDA's estimation, and sponsors will be required to submit paper-based reports during that time period.
The reports would be sent to FDA using its widely used "eSubmitter" system, formally known as its electronic submission gateway (ESG).
FDA's Center for Devices and Radiological Health (CDRH) also expects to launch a website to provide online support and information about submitting the reports, it said.
While FDA received a handful of comments from industry regarding the changes, FDA brushed them aside as either unwarranted or not substantial enough to require changes to be made.
For example, one commentator said FDA's estimate of benefits had not taken into account that some companies would have to institute a system to use FDA's electronic submission system. FDA disagreed, saying most companies that deal with FDA already use the eSubmitter system for other applications, and would thus "already have compatible systems and would be familiar with FDA's ESG."
Accordingly, FDA said it has submitted its electronic 806 reporting request to the Office of Management and Budget (OMB), which will likely provide a response to FDA sometime after May 2014. FDA is accepting additional comments on the proposal until 28 April 2014.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.